Collaboration - January 8, 2016
Bavarian Nordic collaborates with Janssen
Janssen Pharmaceuticals has entered into a collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN technology, jointly with Janssen’s own AdVac technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of HPV chronic infections which can lead to cancer. Under this agreement, Janssen will conduct all clinical development […]
Acquisition - May 18, 2015
Bavarian Nordic Gets Loan
Bavarian Nordic has secured a loan facility of EUR 50 million from the European Investment Bank (EIB). The loan facility has been issued to support the research and development of vaccines against Ebola and other infectious diseases as well as cancer immunotherapies, according to BioSpace.com. The loan facility provides Bavarian Nordic a chance to speed […]
Clinical Trials - May 15, 2015
Solid Tests for Smallpox Vaccine
Results of two pivotal Phase 3 studies of the liquid-frozen formulation of Bavarian Nordic A/S’s IMVAMUNE®, supporting a Biologics License Application for U.S. approval of the vaccine, were announced this week. In addition, the company announced results from a Phase 2 study of freeze-dried IMVAMUNE smallpox vaccine, supporting the clinical requirements for an Emergency Use […]
Clinical Trials - May 14, 2015
Ebola Vaccine Regimen Tested
Preliminary results from a Phase 1 first-in-human study of the Ebola prime-boost vaccine regimen of Bavarian Nordic’s MVA-BN® Filo vaccine and the AdVac® vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson were presented by Janssen at a meeting of the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee. […]
Drug Development Pharma - February 25, 2015
Bavarian Nordic to Present Findings at Symposium
Bavarian Nordic plans to present updated overall survival data from an NCI sponsored combination study of its active prostate cancer immunotherapy candidate PROSTVAC and ipilimumab, an immune checkpoint inhibitor, at the Genitourinary Cancers Symposium in Orlando, FL on Feb. 26. Approximately 20 perecent of men with advanced prostate cancer treated with PROSTVAC and Ipilimumab were alive 80 months after initiating […]
Clinical Trials - December 8, 2014
Bavarian Nordic vs Ebola
Denmark’s Bavarian Nordic announced Dec. 4 that a first subject has been dosed with MVA-BN Filo in a Phase 1 safety and immunogenicity trial, evaluating a heterologous prime-boost regimen of Ebola candidate vaccines. The trial, sponsored by the University of Oxford, is assessing the monovalent cAd3-EBO Z vaccine co-developed by GSK and the U.S. National […]
